Skip Navigation
News & Information Services
 
 
 
 
 
Print This Page
Share this page: More
 

Statement Regarding Single Dose Nevirapine Study in Uganda

December 14, 2004

STATEMENT REGARDING SINGLE DOSE NEVIRAPINE STUDY IN UGANDA

As Johns Hopkins has noted in the past, no deaths, serious reactions or serious adverse events were considered likely to be related to the single dose of nevirapine used in the Uganda study. Further, subsequent reviews have validated the study results and multiple other studies have confirmed the safety and efficacy of nevirapine for prevention of mother to child transmission of HIV. The Centers for Disease Control, the World Health Organization, the National Institutes of Health and African physicians involved in the study all have concluded that nevirapine used as a single dose to prevent maternal to child transmission of HIV is safe, appropriate and effective in this health care setting.

Johns Hopkins stands by the research and confidently awaits results of an independent review of the study by the Institute of Medicine, which should be complete in several months.

Statement from March 2002

- -JHMI- -

 

 

 

 

Traveling for care?

blue suitcase

Whether crossing the country or the globe, we make it easy to access world-class care at Johns Hopkins.

U.S. 1-410-464-6713 (toll free)
International +1-410-614-6424

 

 
 
 
 
 

© The Johns Hopkins University, The Johns Hopkins Hospital, and Johns Hopkins Health System. All rights reserved.

Privacy Policy and Disclaimer